Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated stock has risen 15.4% in a month, driven by strong second-quarter results, higher 2026 guidance, and growing confidence in its post-cystic fibrosis growth story. The company reported second-quarter revenues of $3.33 billion, up 12% year over year, and raised its full-year revenue outlook to $13.1-$13.2 billion from $12.95-$13.1 billion previously. Earnings of $4.73 per share rose around 5% year over year. Vertex's CF products generated revenues of $6.1 billion in the first half of 2026, up 8.4% year over year, with Alyftrek sales of $573.6 million in the second quarter, up 35% sequentially. Non-CF products, including Journavx and Casgevy, are gaining traction, with combined second-quarter sales of $126 million, and the company expects non-CF revenues to exceed $500 million in 2026, up about 185% year over year. Vertex's renal pipeline, including povetacicept for IgAN, is advancing, with an FDA decision expected by Nov. 30, 2026. The stock trades at 27.52 forward earnings, above the industry's 19.44, and the Zacks Consensus Estimate for 2026 earnings has declined to $19.01 per share over the past 30 days. In July 2026, Vertex agreed to acquire Crinetics Pharmaceuticals for about $10 billion, adding rare endocrine diseases as a fifth pillar. Despite headwinds, Vertex remains a Zacks Rank #3 (Hold) stock, with long-term investors advised to retain it.

Vertex Pharmaceuticals reported second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b and completing a US$1.42b share repurchase program. The stock closed at $516.44, which Simply Wall St's narrative model frames as 7.6% undervalued relative to a fair value of $558.68. Vertex's current P/E of 29.7x sits above the US Biotechs industry average of 15.9x and above a fair ratio of 28.2x. The company's pipeline diversification includes programs in pain, kidney, and type 1 diabetes, leveraging genomic and gene-editing technologies.

Sionna Therapeutics shares plunged more than 90% after its lead cystic fibrosis drug candidate SION-719 failed a Phase 2a trial, while Vertex Pharmaceuticals surged to new highs as a key competitive threat was removed. The trial, which tested SION-719 as an add-on to Vertex’s blockbuster Trikafta regimen, did not meet its main activity endpoint, and Sionna will not advance the program. Sionna will now prioritize an earlier-stage SION-451 combo program, but with over $268 million in cash and its lead asset shelved, the stock’s valuation was heavily dependent on SION-719. Vertex, already trading near record levels after raising full-year revenue guidance and proposing a $10 billion acquisition of Crinetics Pharmaceuticals, saw its cystic fibrosis dominance further de-risked.

Vertex Pharmaceuticals reported second-quarter revenue of $3.33 billion, surpassing analyst estimates of $3.19 billion and representing 12.5% year-on-year growth. Adjusted earnings per share came in at $4.73, roughly in line with expectations of $4.75, while adjusted operating income of $1.42 billion beat estimates by 3.9%. The company raised its full-year revenue guidance to $13.15 billion at the midpoint, up from $13.03 billion. During the earnings call, analysts pressed management on topics including dose selection for the Phase II/III OLYMPUS study, payer dynamics for JOURNAVX, and clinical endpoints for next-generation cystic fibrosis and renal therapies.

Vertex Pharmaceuticals shares surged approximately 5.9% in Monday's regular session after Sionna Therapeutics announced its drug SION-719 missed the key activity endpoint in a Phase 2a trial when added to the current standard of care. Sionna is dropping that specific add-on strategy, giving Vertex's dominant cystic-fibrosis franchise more breathing room. Vertex's second-quarter revenue climbed 12% to roughly $3.33 billion, and management raised full-year revenue guidance to $13.1 billion to $13.2 billion. Despite the stock's jump, GuruFocus estimates Vertex's GF Value at $519.20, leaving the shares trading only 1.34% above that fair value estimate at $526.15.

AbCellera Biologics reported a net loss of roughly $55 million for the second quarter of 2026, up from a $35 million loss a year earlier, while total revenue dropped to approximately $4 million from $17 million. The company completed enrollment for the phase 2 study of ABCL-635 in treating hot flashes ahead of schedule, with top-line data expected soon, and secured new T-cell engager collaborations with Vertex and Jazz Pharmaceuticals that added over $110 million in upfront cash. AbCellera maintains a strong liquidity position with over $565 million in cash and equivalents plus roughly $110 million in committed government funding, providing a runway of at least three years. Research and development expenses increased by about $7 million year-over-year, and the company missed its internal goal of moving another program into IND-enabling activities in the first half of 2026. The upcoming phase 2 data for ABCL-635 carries scientific risks, including the unresolved question of whether blocking NK3R in the pre-optic nucleus is necessary for efficacy, and the company acknowledged a pronounced placebo response in similar trials.

Entrada Therapeutics reported its second quarter 2026 financial results and highlighted upcoming clinical milestones. The company expects to report data from the Cohort 1 open-label period of the ELEVATE-44-201 study by year-end 2026, with Cohort 2 data expected in the first quarter of 2027. Data from Cohort 1 of the ELEVATE-45-201 study is anticipated in October 2026, while Cohort 2 dosing is ongoing at an increased dose of 10 milligrams per kilogram with data expected in the first half of 2027. Vertex is on track to report results from the Phase 1/2 trial of VX-670 in people with myotonic dystrophy type 1 in the second half of 2026. For the second quarter, Entrada posted a net loss of 42.8 million dollars, compared to 43.1 million dollars in the same period last year, and held cash, cash equivalents, and marketable securities of 223.0 million dollars as of June 30, 2026.

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026, aiming to broaden its pipeline beyond cystic fibrosis into endocrine and rare diseases. Vertex reported second-quarter 2026 revenue of US$3,333.9 million and net income of US$1,099.8 million, and raised its full-year 2026 revenue guidance to a range of US$13.1 billion to US$13.2 billion. The acquisition comes alongside a recent collaboration with AbCellera on T cell engagers for autoimmune diseases, positioning Vertex against large biotech peers such as Regeneron and Amgen. Investors will watch for integration plans, R&D spending, and clinical progress as the deal approaches closing.

Vertex Pharmaceuticals reported second-quarter 2026 total revenue of $3.3 billion, a 12% increase year-over-year, driven by its cystic fibrosis portfolio and newer products. Global CF revenue grew 11%, with ALYFTREK exceeding $1 billion in the first half of the year. CASGEVY revenue reached $76 million, up over 150% year-over-year, while JOURNAVX contributed $50 million, up from $12 million in the prior-year quarter. The company raised its full-year 2026 revenue guidance to a range of $13.1 billion to $13.2 billion and reported non-GAAP earnings per share of $4.73, a 5% increase. Gross margin was 85.6%, and cash and investments totaled approximately $13.6 billion at quarter-end.

Vertex Pharmaceuticals reported second-quarter revenue of $3.33 billion, beating analyst estimates of $3.19 billion and marking 12.5% year-on-year growth. Adjusted operating income reached $1.42 billion versus estimates of $1.37 billion, representing a 42.7% margin and a 3.9% beat, while adjusted earnings per share of $4.73 were in line with expectations. The company slightly raised its full-year revenue guidance to a midpoint of $13.15 billion, exceeding analyst forecasts by 0.7%. Operating margin declined to 37.4% from 38.8% in the same quarter last year.

Biotechnology and pharmaceutical IPOs have generated a weighted average return of 55% in the U.S. market this year, sharply outperforming the broader market's 4.4% weighted average loss, according to Bloomberg data through July 17. The strong performance is drawing more drug developers to go public, with at least six filing this month, led by Scribe Therapeutics, and the number of completed biotech IPOs in 2026 already surpassing last year's total while proceeds exceed $5 billion, roughly three times the prior year's amount. Parabilis Medicines raised $770.6 million in the largest biotech IPO on record, and Veradermics has gained more than 500% since its February debut, making it the best-performing U.S. IPO across all sectors. The sector's recovery is supported by a 13% gain in the Nasdaq Biotechnology Index, a stable regulatory environment, and renewed acquisition activity, including three deals valued at $10 billion or more announced in the past month involving AbbVie, GSK, and Vertex Pharmaceuticals. Investment bankers note that major fund groups are reallocating capital toward healthcare, though higher interest rates could pose a headwind.

The American Kidney Fund and the IgA Nephropathy Foundation have created new patient guidelines for IgA nephropathy, a rare kidney disease. The guidelines are based on recently updated KDIGO clinical practice guidelines and were developed using patient focus group input and clinician review. They provide plain language explanations of the disease, an overview of available treatment options, and practical guidance for discussing treatment with healthcare teams in a printable format. The resource is available on AKF’s website and will be offered in Spanish, Korean, and simplified Chinese, with an interactive version planned for later this year. The effort is part of AKF’s “A Step Ahead of IgA Nephropathy” educational campaign, supported by sponsors including Novartis Pharmaceuticals Corporation, Otsuka America Pharmaceutical Inc., Travere Therapeutics, Vertex Pharmaceuticals Incorporated, and Calliditas Therapeutics.

Vertex Pharmaceuticals has received expanded FDA approval for its gene therapy Casgevy to treat children as young as 2 years old with sickle cell disease or transfusion-dependent thalassemia. The decision broadens treatment options for a pediatric group with limited alternatives. Vertex shares most recently closed at $485.65, with returns of 7.4% year to date and 36.0% over three years. The expanded approval highlights how Vertex is building out its rare disease franchise around genetic medicines. Investors may watch how Casgevy's real-world use and reimbursement patterns develop in this broader population.

Vertex Pharmaceuticals announced on July 6 that it will acquire Crinetics Pharmaceuticals for $10 billion in cash. The deal gives Vertex access to Palsonify, a medicine approved in 2025 to treat acromegaly, and several pipeline candidates including atumelnant for congenital adrenal hyperplasia. Vertex estimates that Palsonify and the phase 3 assets have a combined peak annual sales potential of about $5 billion, a meaningful addition for a company that generated $12 billion in revenue last year. The acquisition is part of Vertex's strategy to diversify beyond its dominant cystic fibrosis franchise ahead of patent expirations in the late 2030s.

StockStory highlights Vertex Pharmaceuticals as a Nasdaq 100 stock with huge potential while expressing caution on Workday and Mondelez. Vertex, with a market cap of $121.1 billion, posted 13.8% annual revenue growth over five years and a strong free cash flow margin of 24.7%. Workday, valued at $35.03 billion, faces slowing demand with estimated sales growth of 10.9% and trades at 3.3x forward price-to-sales. Mondelez, at a $75.38 billion market cap, saw earnings per share fall 2% annually over three years and has an estimated sales growth of just 2.4%, trading at 18.4x forward P/E.

The idiopathic membranous nephropathy market across the seven major markets is forecast to approach USD 1 billion by 2036, up from approximately USD 130 million in 2025, according to a new report from ResearchAndMarkets.com. The United States represented about 60% of the market in 2025 with a value of roughly USD 85 million, while nearly 89,000 prevalent cases were estimated across the seven major markets that year. The anticipated launch of targeted therapies, including B-cell-directed treatments, melanocortin receptor agonists, and Bruton's tyrosine kinase inhibitors, is expected to drive growth alongside improved biomarker-based diagnosis and higher treatment rates. Key pipeline candidates include Cerium Pharmaceuticals' SNP-ACTH Gel, Hoffmann-La Roche's obinutuzumab, and Vertex Pharmaceuticals' povetacicept, which recently received Fast Track and Priority Medicines designations. Despite rituximab's current leading role, no therapy is specifically approved for idiopathic membranous nephropathy, leaving significant unmet needs related to relapse, treatment resistance, and disease progression.

Vertex Pharmaceuticals received expanded FDA approval for CASGEVY, extending use to children as young as 2 years with sickle cell disease and beta thalassemia. The company also signed a Letter of Intent with Canadian national payers outlining commercial access terms for ALYFTREK, its next-generation cystic fibrosis therapy. CASGEVY now formally reaches pediatric patients, supported by more than 75 authorized treatment centers in the US. The Canadian LOI is a key precursor to public reimbursement for ALYFTREK, with around 3,800 people in Canada now eligible. These updates reinforce Vertex's focus on genetically defined rare diseases and add regulatory and commercial execution angles alongside its existing pipeline and the ongoing US$10 billion Crinetics acquisition.

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $85 per share in cash, a deal valued at about $10 billion in equity value, or $8.8 billion net of estimated cash acquired. The acquisition is a strategic move to build an endocrinology franchise and is expected to close in the third quarter of 2026. Vertex highlighted two lead endocrine assets that it believes could generate more than $5 billion in combined peak annual sales: PALSONIFY, an approved once-daily oral therapy for acromegaly, and atumelnant, a late-stage treatment for congenital adrenal hyperplasia. Vertex plans to finance the purchase with cash on hand and debt, including $4.5 billion in committed bridge financing, and expects the transaction to be accretive to non-GAAP operating income by 2029.

MGM Resorts has reportedly started discussions with People for a potential buyout after Barry Diller’s media company offered to acquire the casino giant in a transaction worth $12.4 billion last month. Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for a total equity value of about $10 billion, or nearly $8.8 billion net of estimated cash acquired. German engine manufacturer Deutz agreed to acquire military vehicle producer FFG Flensburger Fahrzeugbau Gesellschaft in a transaction valued at approximately €1.6 billion, or $1.8 billion. Perfect signed a definitive merger agreement with ProjectNY, an entity controlled by founder and CEO Alice Chang, under which the company will become privately held at $2.00 per share. Axos Nevada, a subsidiary of Axos Financial, announced a definitive agreement to acquire Arc Technologies, a financial technology platform serving technology and growth companies. Qiagen soared 11% after a report that the European molecular testing company is seeing early takeover interest from private equity firms including EQT AB and Advent. Marex Group agreed to acquire Bright Point International to strengthen its presence in the Asia-Pacific region and expand access to China's markets.

CRISPR Therapeutics could be an attractive buy-and-hold option despite its recent underperformance and current lack of profitability. The biotech has multiple catalysts on the way, including results from an ongoing clinical trial of CTX310, an investigational one-time gene-editing treatment designed to permanently lower LDL cholesterol, expected in the second half of the year. Its approved therapy Casgevy, developed with Vertex Pharmaceuticals, recently received a label expansion from the U.S. Food and Drug Administration to include children as young as two, adding 5,500 patients to its addressable market in the U.S. and representing an additional $12.1 billion commercial opportunity at $2.2 million per treatment course. CRISPR Therapeutics is also expanding beyond gene editing through a partnership with Sirius Therapeutics to develop CTX611, a long-acting siRNA therapy designed to prevent dangerous blood clots with just two injections per year. The company's deep pipeline and partnership with a biotech giant position it to potentially expand its approved product portfolio and improve financial results by the end of the decade.

JPMorgan raised its price target on Eli Lilly ahead of its August earnings report, expecting another strong quarter driven by demand for obesity drugs Mounjaro and Zepbound, with estimated total sales of over $20 billion for the quarter, above consensus. Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for about $10 billion, a deal that will expand Vertex's pipeline and long-term growth strategy. Meta Platforms disclosed in a court filing that four states are seeking $1.4 trillion in penalties over claims it designed Facebook and Instagram to be addictive to children.

StockStory identified three cash-heavy companies with strong balance sheets and growth prospects. Remitly holds a net cash position of $609.8 million, representing 15.4% of its market cap, and has seen active customers grow 28.4% annually over two years. Vertex Pharmaceuticals has a net cash position of $5.26 billion, or 4.7% of its market cap, with 13.8% annual sales growth over five years. Ameriprise Financial's net cash position stands at $4.86 billion, 12% of its market cap, supported by share buybacks and 18.7% annual tangible book value per share growth.

Vertex Pharmaceuticals has signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, a new triple combination therapy for cystic fibrosis. The agreement follows positive reimbursement recommendations from Canada's Drug Agency in December 2025 and INESSS in April 2026. Approximately 3,800 people across Canada are now eligible for ALYFTREK, with up to 60 individuals potentially eligible for a medicine that treats the underlying cause of their disease for the first time. Vertex will now initiate discussions with provinces and territories to support public listing of the drug.

Some smart investors are favoring Vertex Pharmaceuticals over SpaceX, citing Vertex's greater market dominance and more appealing risk-reward profile. Vertex holds a virtual monopoly in cystic fibrosis treatments with all five approved therapies, while SpaceX faces upcoming competition from Amazon's Project Kuiper. Vertex posted adjusted earnings of $4.7 billion last year, compared with SpaceX's net loss of $4.9 billion. The company also has multiple potentially transformative product launches on the way, including an FDA decision on povetacicept for immunoglobulin A nephropathy by November 30, 2026, and late-stage studies for zimislecel in severe Type 1 diabetes. Vertex's shares trade at a forward price-to-sales multiple of around 10 times, versus SpaceX's 56.7 times projected 2026 sales.

AbbVie reported first-quarter revenues of $15 billion, up 12.4% year on year and exceeding analysts' expectations by 1.7%. Among the 11 therapeutics stocks tracked, Moderna delivered the fastest revenue growth with $389 million, a 260% increase that beat estimates by 55.8%. United Therapeutics posted the weakest performance, with revenues of $781.5 million, down 1.6% and missing expectations by 1.9%. Vertex Pharmaceuticals reported $2.99 billion in revenue, up 8.2% and beating estimates by 1.2%, while Halozyme Therapeutics recorded $376.7 million, up 42.2% and exceeding expectations by 6.1%. Overall, the group's revenues surpassed consensus estimates by 14.5%, and share prices have risen an average of 18.9% since the latest earnings results.

The FDA has approved expanded use of Vertex Pharmaceuticals' gene therapy CASGEVY for children as young as two years old with sickle cell disease and transfusion-dependent beta thalassemia. This makes CASGEVY the first gene therapy of its kind available to this pediatric group in the U.S. Vertex estimates that roughly 5,500 additional children in the U.S. may now be eligible for the one-time treatment. The approval significantly widens the treated patient pool for CASGEVY, which is already approved for patients 12 years and older.

Vertex Pharmaceuticals is favored over Arcutis Biotherapeutics as the better pharmaceutical stock to buy in 2026, according to a Motley Fool analysis. Arcutis, which markets the Zoryve dermatology line, saw revenue double to $376.1 million in fiscal 2025 but remains unprofitable with a net loss of $16.1 million, while Vertex generated $12 billion in revenue and nearly $4 billion in net income. The analysis notes that Arcutis achieved positive cash flow in the first quarter of fiscal 2026, yet its main product faces demand fluctuations tied to consumer spending and seasonality. Vertex, dominant in cystic fibrosis treatments covering 95% of U.S. patients, is expanding into gene editing and pain management, with Wall Street projecting sales to exceed $13 billion this year. The conclusion points to Vertex's established profitability, expanding market, and reasonable forward price-to-earnings ratio as decisive factors.

Vertex Pharmaceuticals is favored over Dyne Therapeutics as the better drug innovator stock for 2026, according to an analysis by The Motley Fool. Dyne Therapeutics is a clinical-stage company with no revenue, reporting a net loss of $446.2 million in fiscal 2025, while Vertex posted $12 billion in revenue and nearly $4 billion in net income. Vertex's cystic fibrosis portfolio now covers 95% of U.S. patients and is expanding globally, with a promising pipeline including povetacicept for IgA nephropathy. Dyne's first product for Duchenne muscular dystrophy is expected in early fiscal 2027, with analysts projecting $53 million in sales that year and over $1 billion by 2030. Despite Dyne's growth potential, Vertex's strong profitability, heavy R&D investment, and reasonable forward price-to-earnings ratio make it the preferred choice.

The nephrotic syndrome market across the seven major markets reached approximately USD 400 million in 2025, with the United States holding the largest share. The total diagnosed prevalent cases in these markets were around 800,000 in 2025, and this number is expected to rise during the 2026 to 2036 forecast period. Growth is being propelled by a robust pipeline of emerging therapies, including Inaxaplin from Vertex Pharmaceuticals, Apecotrep from Boehringer Ingelheim, and GAZYVA from Roche, which are expected to launch and transform the treatment landscape. Recent clinical developments include positive Phase III results for GAZYVA in primary membranous nephropathy and a Phase II study showing Apecotrep reduced proteinuria by 40 percent compared with placebo in focal segmental glomerulosclerosis patients.

HCA Healthcare announced new research published in The New England Journal of Medicine showing promising results from a CRISPR-based gene-editing therapy in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. The study, led by Dr. Haydar Frangoul of HCA Healthcare's TriStar Centennial Children's Hospital, is the first published data evaluating exagamglogene autotemcel in this age group. Among participants followed long enough to assess primary endpoints, all eight children with beta thalassemia achieved transfusion independence for at least 12 months, and all eight with sickle cell disease remained free from severe vaso-occlusive crises for at least 12 months. The therapy is currently FDA-approved for patients ages 12 and older, and these findings suggest potential for earlier intervention before cumulative organ damage occurs. The study was sponsored by Vertex Pharmaceuticals and involved 26 children across two phase 3 trials.

CRISPR Therapeutics AG and Vertex Pharmaceuticals present contrasting investment profiles for 2026, with Vertex offering a profitable, cash-generating cystic fibrosis franchise and CRISPR representing a high-risk, pure-play gene-editing bet. CRISPR's FY 2025 revenue fell roughly 90% to nearly $3.5 million, with a net loss of approximately $581.6 million, while Vertex generated close to $12 billion in revenue and net income of approximately $4.0 billion. CRISPR carries a low debt-to-equity ratio of roughly 0.2x and a current ratio of approximately 13.3x, but negative free cash flow of nearly $345.9 million, whereas Vertex posted strong free cash flow of nearly $3.2 billion with a debt-to-equity ratio of approximately 0.4x. Vertex trades at a forward P/E of 25.3x and a price-to-sales ratio of 10x, compared to CRISPR's forward P/E of 18.6x and price-to-sales ratio of 1270x. The two companies share profits from their joint gene-editing therapy CASGEVY on a 40% to 60% split, but CRISPR faces risks including a $600 million convertible note issuance in Q1 2026 and intellectual property litigation from ToolGen, while Vertex contends with revenue concentration in cystic fibrosis and clinical setbacks such as the RewinD-LB trial failure.

The IgA nephropathy clinical trial space is intensifying, with more than 25 companies actively developing over 30 pipeline drugs, according to a new report from DelveInsight. Key players include Haisco Pharmaceutical Group, Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca, Roche, Ionis Pharmaceuticals, Takeda, Arrowhead Pharmaceuticals, and others. Promising therapies in various trial phases include HSK39297, Zigakibart, Povetacicept, Felzartamab, Atacicept, ULTOMIRIS, Sefaxersen, TAK-079, ARO-C3, NM8074, WAL0921, KP104, PS-002, BHV-1400, CM313, NTQ5082, RNK288, and IFX 301. Approximately 12 or more drugs are in late-stage development, targeting mechanisms such as Complement Factor B inhibition, BAFF and APRIL antagonism, antibody-dependent cell cytotoxicity, Gd-IgA1 degradation, RNA interference, and CD38 antagonism. Recent milestones include positive Phase III data for Povetacicept and Atacicept, and publication of telitacicept results in the New England Journal of Medicine.